Amylyx Pharmaceuticals, Inc.

AMLX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001658551

C/D

on the C/D boundary of 367 graded peers in healthcare

rank 227 of 367; percentile 61.7; sampling error 2.5 points; lower is stronger



C/D, the tortoise



Scoreboard	
Profitability	D percentile 71.7
Solvency	A/B percentile 21.1
Growth and financing	D percentile 63.5
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $332.6M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	degenerate inputs not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 3, 2026 258 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$30.29 2026-11-13; market equity $3.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 3, 2026

Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality. Our current pipeline is represented in the table below.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 71.7						
Gross profitability	0.0%	32.3%		95.7	365	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing						
Accruals ratio	(8.1%)	(6.6%)		47.6	799	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 4						
Solvency, sleeve percentile 21.1						
Twelve-month failure probability	0.07%	0.08%		41.8	245	2026-09-30
Altman Z double-prime	7.18	(0.31)		13.5	743	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
one or more required annual facts are missing						
Current ratio	14.27x	2.96x		8.1	825	2025-12-31
Growth and financing, sleeve percentile 63.5						
Revenue growth, three-year compound	not computable	10.1%				
current value must be positive and the base must exceed $100,000						
Free cash flow growth, three-year compound	not computable	11.0%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(5.3%)	2.3%		62.9	693	2025-12-31
Net share issuance, one year	24.8%	2.4%		64.2	627	2026-02-23

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
222	Cryoport, Inc. (CYRX)	60.4	C/D	late filer
223	Rocket Pharmaceuticals, Inc. (RCKT)	60.7	C/D	degenerate inputs
224	Tango Therapeutics, Inc. (TNGX)	60.9	C/D	dilution
225	Teva Pharmaceutical Industries Ltd. (TEVA)	61.2	C/D	
226	Akebia Therapeutics, Inc. (AKBA)	61.5	C/D	fortress balance sheet
227	Amylyx Pharmaceuticals, Inc. (AMLX)	61.7	C/D	degenerate inputs
228	Embecta Corp. (EMBC)	62.0	C/D	late filer
229	Lenz Therapeutics, Inc. (LENZ)	62.3	C/D	short runway
230	Biogen Inc. (BIIB)	62.6	D	
231	Beam Therapeutics Inc. (BEAM)	62.8	D	
232	AbbVie Inc. (ABBV)	63.1	D	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	108.9%	(1.5%)	92
Distance from 52-week high	(23.6%)	(32.0%)	57
EBIT to enterprise value	not computable	(1.8%)	
Free cash flow yield	(3.2%)	(1.0%)	43
Book value to price	0.19	0.29	39
Sales to price	0.00	0.29	0
Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	0.57	(0.18)	92

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$240.1M
Operating cash flow, four quarters	-$129.9M
Months of runway	22.2
Days since last periodic filing	11 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$44.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$0	2025-12-31	2026-03-03	10-K	26-086645
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$0	2025-12-31	2026-03-03	10-K	26-086645
3	assets	us-gaap:Assets	$332.6M	2025-12-31	2026-03-03	10-K	26-086645
4	net income	us-gaap:NetIncomeLoss	-$144.7M	2025-12-31	2026-03-03	10-K	26-086645
5	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$123.3M	2025-12-31	2026-03-03	10-K	26-086645
6	assets	us-gaap:Assets	$193.6M	2024-12-31	2026-03-03	10-K	26-086645
7	current assets	us-gaap:AssetsCurrent	$323.7M	2025-12-31	2026-03-03	10-K	26-086645
8	current liabilities	us-gaap:LiabilitiesCurrent	$22.7M	2025-12-31	2026-03-03	10-K	26-086645
9	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$751.4M	2025-12-31	2026-03-03	10-K	26-086645
10	operating income	us-gaap:OperatingIncomeLoss	-$153.3M	2025-12-31	2026-03-03	10-K	26-086645
11	book equity	us-gaap:StockholdersEquity	$305.3M	2025-12-31	2026-03-03	10-K	26-086645
12	liabilities	us-gaap:Liabilities	$27.4M	2025-12-31	2026-03-03	10-K	26-086645
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$87.4M	2024-12-31	2026-03-03	10-K	26-086645
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$380.8M	2023-12-31	2025-03-04	10-K	25-031309
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$22.2M	2022-12-31	2024-02-22	10-K	24-018447
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$138,000	2025-12-31	2026-03-03	10-K	26-086645
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$167.6M	2024-12-31	2026-03-03	10-K	26-086645
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$157,000	2024-12-31	2026-03-03	10-K	26-086645

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$11.9M	2023-12-31	2025-03-04	10-K	25-031309
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.2M	2023-12-31	2025-03-04	10-K	25-031309
21	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$179.9M	2022-12-31	2024-02-22	10-K	24-018447
22	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.5M	2022-12-31	2024-02-22	10-K	24-018447
23	depreciation amortization	us-gaap:Depreciation	$525,000	2025-12-31	2026-03-03	10-K	26-086645
24	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$144.7M	2025-12-31	2026-03-03	10-K	26-086645
25	income tax	us-gaap:IncomeTaxExpenseBenefit	$46,000	2025-12-31	2026-03-03	10-K	26-086645
26	current assets	us-gaap:AssetsCurrent	$189.4M	2024-12-31	2026-03-03	10-K	26-086645
27	current liabilities	us-gaap:LiabilitiesCurrent	$28.4M	2024-12-31	2026-03-03	10-K	26-086645
28	assets	us-gaap:Assets	$517.5M	2023-12-31	2025-03-04	10-K	25-031309
29	assets	us-gaap:Assets	$391.5M	2022-12-31	2024-02-22	10-K	24-018447
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	110,536,944	2026-02-23	2026-03-03	10-K	26-086645
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	88,602,468	2025-02-28	2025-03-04	10-K	25-031309

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.